The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

About MAD for Cancer

Over the last decade it has become evident that a tumor no longer can be regarded as only a collection of cancer cells, but constitutes an organ itself. Consequently, the only successful strategy to fight cancer will be to combine know-how from areas involving all parts of the tumor environment. The MAD for Cancer Program is a unique concept in that it brings together several different facets of cancer biology from four faculties into a multifocal approach.

MAD for Cancer encompasses early diagnosis, patient stratification, and targeted therapies attacking every possible tumor stem cell, cancer cell, stromal cell, as well as blood supply of the tumor, backed by cutting edge bioinformatics, and studies on resilience. The hallmark of this battle is the creative force generated by national and international collaborators between scientific areas, such as clinical oncology, immunology, genomics, proteomics, chemical biology, nanotechnology, imaging, psychology and behavioral science.

The implementation of scientific results that benefit the patient often takes a long time, consequently hindering the chance for an increased life expectancy. However, within the MAD for Cancer Program there is already a strong track record for the rapid implementation of research into a clinic for the benefit of the patients.